Lisa Boggio is an Oncology physician affiliated with Rush University Medical Center. OpenAlex indexes 75 publications with 2,650 citations (h-index 22).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1725 W Harrison St
Suite 834
Chicago, IL 606123841
Telephone
312-942-5157Provider last certified this registry record 16 Nov 2020.
Industry payments
25 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Octapharma USA, Inc.Program year20253 payments$18,840openpaymentsdata.cms.gov ↗
- SANOFI US SERVICES INC.Program year20251 payment$11,760openpaymentsdata.cms.gov ↗
- Novo Nordisk IncProgram year20257 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
54.9%Factor Xa inhibitor30.9%Eliquis74%Xarelto26%Part D<11 patientsVitamin K antagonist16.7%Warfarin Sodium100%Part D<11 patients+ 1 more class in this area
Respiratory
23.5%Opioid Agonist23.5%Hydrocodone-Acetaminophen100%Part D<11 patientsNervous system
14.8%Opioid Agonist7.4%Methadone Hcl100%Part D<11 patientsgamma-Aminobutyric Acid A Receptor Positive Modulator7.4%Zolpidem Tartrate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia
British Journal of Haematology
2022 - Molecular pathogenesis and heterogeneity in type 3 VWD families in U.S. Zimmerman program
Journal of Thrombosis and Haemostasis
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Christopher Goetz, MD
Rush University Medical Center
Theodore Pincus, MD
Rush University Medical Center
Christopher Seder, MD
Rush University Medical Center
Melody Cobleigh, MD
Rush University Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”